Press Release

Amedisys Reports First Quarter 2022 Financial Results and Reaffirms 2022 Guidance

04/27/2022

BATON ROUGE, La., April 27, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2022.

Three-Month Periods Ended March 31, 2022 and 2021

  • Net service revenue increased $8.2 million to $545.3 million compared to $537.1 million in 2021.
  • Net income attributable to Amedisys, Inc. of $31.7 million compared to $49.9 million in 2021.
  • Net income attributable to Amedisys, Inc. per diluted share of $0.97 compared to $1.50 in 2021.

Adjusted Quarterly Results*

  • Adjusted EBITDA of $66.3 million compared to $78.6 million in 2021.
  • Adjusted net income attributable to Amedisys, Inc. of $40.1 million compared to $51.1 million in 2021.
  • Adjusted net income attributable to Amedisys, Inc. per diluted share of $1.23 compared to $1.54 in 2021.

* See pages 2 and 11 - 12 for the definition and reconciliations of non-GAAP financial measures to GAAP measures.

Chris Gerard, President and Chief Executive Officer stated, “The start of 2022 saw continuation of the COVID driven challenges we and the industry faced over the past few years and further highlighted how Amedisys’ differentiated strategy presents us with significant opportunities as we navigate an ever-changing landscape. We saw Omicron impact our business and the number of clinicians on quarantine in January; we signed two home health acquisitions and are well on our way to additional inorganic growth; we saw discharge rates in our hospice business reach new highs and subsequently have begun to pull back; and we continued to field a tremendous amount of interest for Hospital at Home and other high-acuity care products. The competitive landscape continues to evolve as COVID impacts linger, yet we still delivered financial results this quarter that I am very proud of. Through the ups and downs, our 21,000 employees continued to do what they do best: providing (or enabling our clinicians to provide) the highest quality care to patients wherever they call home. A sincere thank you to all our employees; it is your care, passion and effort that continues to propel us forward.”

2022 Guidance

We are reaffirming our previously issued guidance:

  • Adjusted net service revenue is anticipated to be in the range of $2.330 billion to $2.365 billion.
  • Adjusted EBITDA is anticipated to be in the range of $275 million to $285 million.
  • Adjusted diluted earnings per share is anticipated to be in the range of $5.23 to $5.45 based on an estimated 33.2 million shares outstanding.

This guidance excludes the effects of any future acquisitions, if any are made. COVID-19 has continued to impact the operating metrics typically used to forecast both growth and cost assumptions for both core Amedisys and Contessa. We are basing our guidance on our current operating environment. COVID-19 continues to evolve in both the disease itself as well as disruptions to the healthcare systems and the economy. Any future regulations or government interventions, spike in clinicians and business development staff on quarantine, staffing shortages due to current and proposed federal, state and local vaccine mandates, reduction in elective procedures, change in patient behavior and further decline in senior living occupancy could impact our ability to achieve this guidance.

We urge caution in considering the current trends and 2022 guidance disclosed in this press release. The home health, hospice, personal care and high acuity care industries are highly competitive and subject to intensive regulations, and trends are subject to numerous factors, risks, and uncertainties, some of which are referenced in the cautionary language below and others that are described more fully in our reports filed with the Securities and Exchange Commission (“SEC”) including our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, subsequent Quarterly Reports on Form 10-Q, and current reports on Form 8-K which can be found on the SEC’s internet website, http://www.sec.gov , and our internet website, http://www.amedisys.com .

Earnings Call and Webcast Information

Amedisys will host a conference call on Thursday, April 28, 2022, at 11:00 a.m. Eastern Time to discuss its first quarter results. To participate on the conference call, please call before 11:00 a.m. Eastern Time to either (877) 524-8416 (Toll-Free) or (412) 902-1028 (Toll). A replay of the conference call will be available through May 28, 2022 by dialing (877) 660-6853 (Toll-Free) or (201) 612-7415 (Toll) and entering conference ID #13729119.

A live webcast of the call will be accessible through our website on our Investor Relations section at the following web address: http://investors.amedisys.com.

Non-GAAP Financial Measures

This press release includes reconciliations of the most comparable financial measures calculated and presented in accordance with accounting principles generally accepted in the U.S. (“GAAP”) to non-GAAP financial measures. The non-GAAP financial measures as defined under SEC rules are as follows: (1) adjusted EBITDA, defined as net income attributable to Amedisys, Inc. before net interest expense, provision for income taxes and depreciation and amortization, excluding certain items; (2) adjusted other operating income, defined as other operating income excluding certain items; (3) adjusted net income attributable to Amedisys, Inc., defined as net income attributable to Amedisys, Inc. excluding certain items; and (4) adjusted net income attributable to Amedisys, Inc. per diluted share, defined as net income attributable to Amedisys, Inc. common stockholders per diluted share excluding certain items. Management believes that these non-GAAP financial measures, when reviewed in conjunction with GAAP financial measures, are useful gauges of our current performance and are also included in internal management reporting. These non-GAAP financial measures should be considered in addition to, and not more meaningful than or as an alternative to the GAAP financial measures presented in this earnings release and the company’s financial statements. Non-GAAP measures as presented herein may not be comparable to similarly titled measures reported by other companies since not all companies calculate these non-GAAP measures consistently.

Additional Information

Amedisys, Inc. (the “Company”) is a leading healthcare at home company delivering personalized home health, hospice, personal care and high acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care, inpatient hospital, palliative and skilled nursing facility (“SNF”) care in their homes, recovery and rehabilitation after an operation or injury, care focused on empowering our patients to manage a chronic disease, or hospice care at the end of life. More than 3,000 hospitals and 90,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. With approximately 21,000 employees in 548 care centers within 38 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 445,000 patients in need every year. For more information about the Company, please visit: www.amedisys.com.

We use our website as a channel of distribution for important company information. Important information, including press releases, investor presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled “Investors” on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website.

Forward-Looking Statements

When included in this press release, words like “believes,” “belief,” “expects,” “strategy,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “will,” “could,” “would,” “should” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: the impact of the novel coronavirus pandemic (“COVID-19”), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations; the impact of current and proposed federal, state and local vaccine mandates, including potential staff shortages; changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis; changes in Medicare and other medical payment levels; our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively; competition in the healthcare industry; changes in the case mix of patients and payment methodologies; changes in estimates and judgments associated with critical accounting policies; our ability to maintain or establish new patient referral sources; our ability to consistently provide high-quality care; our ability to attract and retain qualified personnel; our ability to keep our patients and employees safe; changes in payments and covered services by federal and state governments; future cost containment initiatives undertaken by third-party payors; our access to financing; our ability to meet debt service requirements and comply with covenants in debt agreements; business disruptions due to natural disasters or acts of terrorism, widespread protests or civil unrest; our ability to integrate, manage and keep our information systems secure; our ability to realize the anticipated benefits of acquisitions, investments and joint ventures; and changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

     
Contact: Investor Contact: Media Contact:
  Amedisys, Inc. Amedisys, Inc.
  Nick Muscato Kendra Kimmons
  Chief Strategy Officer Vice President, Marketing & Communications
  (615) 928- 5452 (225) 299-3720
  IR@amedisys.com kendra.kimmons@amedisys.com
     

 

 
AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands, except per share data)
(Unaudited)
     
  For the Three-Month
Periods Ended March 31,
  2022
  2021
Net service revenue $ 545,257     $ 537,144  
Other operating income         8,701  
Cost of service, excluding depreciation and amortization   304,820       297,203  
General and administrative expenses:    
Salaries and benefits   123,480       115,825  
Non-cash compensation   7,347       7,307  
Other   53,640       49,106  
Depreciation and amortization   8,008       7,555  
Operating expenses   497,295       476,996  
Operating income   47,962       68,849  
Other income (expense):    
Interest income   13       24  
Interest expense   (3,173 )     (2,072 )
Equity in (loss) earnings from equity method investments   (1,403 )     1,118  
Miscellaneous, net   333       288  
Total other expense, net   (4,230 )     (642 )
Income before income taxes   43,732       68,207  
Income tax expense   (12,019 )     (17,915 )
Net income   31,713       50,292  
Net income attributable to noncontrolling interests   (42 )     (422 )
Net income attributable to Amedisys, Inc. $ 31,671     $ 49,870  
Basic earnings per common share:              
Net income attributable to Amedisys, Inc. common stockholders $ 0.97     $ 1.52  
Weighted average shares outstanding   32,555       32,780  
Diluted earnings per common share:    
Net income attributable to Amedisys, Inc. common stockholders $ 0.97     $ 1.50  
Weighted average shares outstanding   32,766       33,190  
               

 

 
AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except share data)
     
  March 31, 2022
(unaudited)
  December 31,
2021
ASSETS              
Current assets:              
Cash and cash equivalents $ 67,834     $ 42,694  
Restricted cash   3,075       3,075  
Patient accounts receivable   293,579       274,961  
Prepaid expenses   17,221       10,356  
Other current assets   10,776       25,598  
Total current assets   392,485       356,684  
Property and equipment, net of accumulated depreciation of $98,573 and $96,937   17,295       18,435  
Operating lease right of use assets   102,801       101,257  
Goodwill   1,204,638       1,196,090  
Intangible assets, net of accumulated amortization of $18,590 and $19,900   106,534       111,190  
Deferred income tax assets         289  
Other assets   84,639       73,023  
Total assets $ 1,908,392     $ 1,856,968  
               
LIABILITIES AND EQUITY              
Current liabilities:              
Accounts payable $ 36,621     $ 38,217  
Payroll and employee benefits   151,279       141,001  
Accrued expenses   148,044       150,836  
Current portion of long-term obligations   12,309       12,995  
Current portion of operating lease liabilities   31,901       31,233  
Total current liabilities   380,154       374,282  
Long-term obligations, less current portion   429,453       432,075  
Operating lease liabilities, less current portion   70,295       69,309  
Deferred income tax liabilities   2,915        
Other long-term obligations   4,923       4,979  
Total liabilities   887,740       880,645  
Equity:              
Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding          
Common stock, $0.001 par value, 60,000,000 shares authorized; 37,763,705 and 37,674,868 shares issued; and 32,566,636 and 32,509,969 shares outstanding   38       38  
Additional paid-in capital   736,536       728,118  
Treasury stock, at cost 5,197,069 and 5,164,899 shares of common stock   (440,550 )     (435,868 )
Retained earnings   670,734       639,063  
Total Amedisys, Inc. stockholders’ equity   966,758       931,351  
Noncontrolling interests   53,894       44,972  
Total equity   1,020,652       976,323  
Total liabilities and equity $ 1,908,392     $ 1,856,968  
               

 

 
AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS AND DAYS REVENUE OUTSTANDING
(Amounts in thousands, except statistical information)
(Unaudited)
     
  For the Three-Month
Periods Ended March 31,
  2022
  2021
Cash Flows from Operating Activities:              
Net income $ 31,713     $ 50,292  
Adjustments to reconcile net income to net cash provided by operating activities:              
Depreciation and amortization   8,008       7,555  
Non-cash compensation   7,347       7,307  
Amortization and impairment of operating lease right of use assets   10,096       9,850  
Loss on disposal of property and equipment   5       14  
Deferred income taxes   3,205       7,411  
Equity in loss (earnings) from equity method investments   1,403       (1,118 )
Amortization of deferred debt issuance costs/debt discount   248       216  
Return on equity method investments   1,710       1,500  
Changes in operating assets and liabilities, net of impact of acquisitions:              
Patient accounts receivable   (18,618 )     (20,448 )
Other current assets   7,882       (2,874 )
Other assets   247       (115 )
Accounts payable   (2,115 )     (3,374 )
Accrued expenses   7,483       8,370  
Other long-term obligations   (57 )     (808 )
Operating lease liabilities   (9,187 )     (9,014 )
Operating lease right of use assets   (749 )     (762 )
Net cash provided by operating activities   48,621       54,002  
               
Cash Flows from Investing Activities:              
Proceeds from the sale of deferred compensation plan assets   22       19  
Proceeds from the sale of property and equipment   37       42  
Purchases of property and equipment   (902 )     (1,618 )
Investments in technology assets   (236 )      
Other investments   (15,000 )      
Net cash used in investing activities   (16,079 )     (1,557 )
               
Cash Flows from Financing Activities:              
Proceeds from issuance of stock upon exercise of stock options   86       364  
Proceeds from issuance of stock to employee stock purchase plan   985       1,048  
Shares withheld to pay taxes on non-cash compensation   (4,682 )     (6,774 )
Noncontrolling interest contributions   652        
Noncontrolling interest distributions   (672 )     (518 )
Proceeds from borrowings under revolving line of credit         215,200  
Repayments of borrowings under revolving line of credit         (186,200 )
Principal payments of long-term obligations   (3,771 )     (2,692 )
Purchase of company stock         (72,886 )
Provider relief fund advance         (5,000 )
Net cash used in financing activities   (7,402 )     (57,458 )
Net increase (decrease) in cash, cash equivalents and restricted cash   25,140       (5,013 )
Cash, cash equivalents and restricted cash at beginning of period   45,769       83,357  
Cash, cash equivalents and restricted cash at end of period $ 70,909     $ 78,344  
               
Supplemental Disclosures of Cash Flow Information:              
Cash paid for interest $ 1,864     $ 1,011  
Cash paid for income taxes, net of refunds received $ 551     $ 971  
Cash paid for operating lease liabilities $ 9,936     $ 9,776  
Cash paid for finance lease liabilities $ 357     $ 503  
               
Supplemental Disclosures of Non-Cash Activity:              
Right of use assets obtained in exchange for operating lease liabilities $ 11,203     $ 10,548  
Right of use assets obtained in exchange for finance lease liabilities $ 216     $ 177  
Reductions to right of use assets resulting from reductions to operating lease liabilities $ 299     $ 279  
Noncontrolling interest contribution $ 8,900     $  
Days revenue outstanding (1)   46.3       43.9  

(1) Our calculation of days revenue outstanding at March 31, 2022 and 2021 is derived by dividing our ending patient accounts receivable by our average daily patient revenue for the three-month periods ended March 31, 2022 and 2021, respectively.


AMEDISYS, INC. AND SUBSIDIARIES
SEGMENT INFORMATION
(Amounts in millions, except statistical information)
(Unaudited)

Segment Information - Home Health

  For the Three-Month Periods
Ended March 31,
  2022
  2021
Financial Information (in millions) :              
Medicare $ 224.1     $ 221.4  
Non-Medicare   111.4       107.2  
Net service revenue   335.5       328.6  
Other operating income         5.0  
Cost of service   185.0       183.0  
Gross margin   150.5       150.6  
Other operating expenses   83.2       80.1  
Depreciation and amortization   0.9       1.0  
Operating income $ 66.4     $ 69.5  
Same Store Growth (1):              
Medicare revenue   1 %     9 %
Non-Medicare revenue   4 %     8 %
Total admissions   2 %     5 %
Total volume (2) (6)   %     6 %
Key Statistical Data - Total (3):              
Admissions   91,714       89,830  
Recertifications (6)   42,850       43,811  
Total volume (6)   134,564       133,641  
Medicare completed episodes   74,406       75,332  
Average Medicare revenue per completed episode (4) $ 3,013     $ 2,931  
Medicare visits per completed episode (5)   13.0       13.9  
Visiting clinician cost per visit $ 97.26     $ 90.32  
Clinical manager cost per visit   10.62       9.50  
Total cost per visit $ 107.88     $ 99.82  
Visits   1,715,144       1,832,912  

(1) Same store information represents the percent change in our Medicare, Non-Medicare and Total revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare and Total revenue, admissions or volume of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.
(2) Total volume includes all admissions and recertifications.
(3) Total includes acquisitions, start-ups and denovos.
(4) Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care. Average Medicare revenue per completed episode reflects the suspension of sequestration effective May 1, 2020.
(5) Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.
(6) Prior year amounts have been recast to conform to the current year calculation.

Segment Information - Hospice

  For the Three-Month Periods
Ended March 31,
  2022
  2021
Financial Information (in millions):    
Medicare $ 182.5     $ 181.5  
Non-Medicare   10.6       10.0  
Net service revenue   193.1       191.5  
Other operating income         3.7  
Cost of service   106.4       101.6  
Gross margin   86.7       93.6  
Other operating expenses   51.3       46.5  
Depreciation and amortization   0.6       0.6  
Operating income $ 34.8     $ 46.5  
Same Store Growth (1):              
Medicare revenue   1 %     (2 %)
Hospice admissions   2 %     5 %
Average daily census   (3 %)     (4 %)
Key Statistical Data - Total (2):              
Hospice admissions   13,886       13,683  
Average daily census   12,920       13,321  
Revenue per day, net $ 166.04     $ 159.76  
Cost of service per day $ 91.48     $ 84.80  
Average discharge length of stay   89       94  

(1) Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.
(2) Total includes acquisitions and denovos.

Segment Information - Personal Care

  For the Three-Month Periods
Ended March 31,
  2022
  2021
Financial Information (in millions):              
Medicare $     $  
Non-Medicare   14.0       17.0  
Net service revenue   14.0       17.0  
Other operating income          
Cost of service   10.8       12.6  
Gross margin   3.2       4.4  
Other operating expenses   2.2       3.0  
Depreciation and amortization   0.1       0.1  
Operating income $ 0.9     $ 1.3  
Key Statistical Data - Total:              
Billable hours   451,032       607,437  
Clients served   7,479       9,759  
Shifts   193,742       257,609  
Revenue per hour $ 30.95     $ 27.95  
Revenue per shift $ 72.04     $ 65.92  
Hours per shift   2.3       2.4  

Segment Information - High Acuity Care

  For the Three-Month Periods
Ended March 31,
  2022
  2021
Financial Information (in millions):              
Medicare $     $  
Non-Medicare   2.7        
Net service revenue   2.7        
Other operating income          
Cost of service   2.6        
Gross margin   0.1        
Other operating expenses   7.1        
Depreciation and amortization   0.8        
Operating loss $ (7.8 )   $  
Key Statistical Data - Total:              
Full risk admissions   106        
Limited risk admissions   227        
Total admissions   333        
Number of joint ventures   9        

Segment Information - Corporate

  For the Three-Month Periods
Ended March 31,
  2022
  2021
Financial Information (in millions):              
Other operating expenses $ 40.7     $ 42.6  
Depreciation and amortization   5.6       5.9  
Total operating expenses $ 46.3     $ 48.5  
               


AMEDISYS, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES TO GAAP MEASURES
(Amounts in thousands)
(Unaudited)

Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (“Adjusted EBITDA”) Reconciliation:

  For the Three-Month Periods
Ended March 31,
  2022
  2021
Net income attributable to Amedisys, Inc. $ 31,671     $ 49,870  
Add:    
Income tax expense   12,019       17,915  
Interest expense, net   3,160       2,048  
Depreciation and amortization   8,008       7,555  
Certain items (1)   11,450       1,712  
Interest component of certain items (1)         (517 )
Adjusted EBITDA (2) (6) $ 66,308     $ 78,583  

Adjusted Other Operating Income Reconciliation:

  For the Three-Month Periods
Ended March 31,
  2022
  2021
Other operating income $     $ 8,701  
Add:    
Certain items (1)         (8,701 )
Adjusted other operating income (3) (6) $     $  

Adjusted Net Income Attributable to Amedisys, Inc Reconciliation:

  For the Three-Month Periods
Ended March 31,
  2022
  2021
Net income attributable to Amedisys, Inc. $ 31,671     $ 49,870  
Add:              
Certain items (1)   8,473       1,267  
Adjusted net income attributable to Amedisys, Inc. (4) (6) $ 40,144     $ 51,137  

Adjusted Net Income Attributable to Amedisys, Inc. per Diluted Share Reconciliation:

  For the Three-Month Periods
Ended March 31,
  2022
  2021
Net income attributable to Amedisys, Inc. common stockholders per diluted share $ 0.97     $ 1.50  
Add:              
Certain items (1)   0.26       0.04  
Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share (5) (6) $ 1.23     $ 1.54  

(1) The following details the certain items for the three-month periods ended March 31, 2022 and 2021:

Certain Items:

  For the Three-Month Periods
Ended March 31,
  2022
  2021
  (Income) Expense
  (Income) Expense
Certain Items Impacting Other Operating Income:              
CARES Act funds $     $ (8,701 )
Certain Items Impacting Cost of Service:              
COVID-19 costs   3,733       8,480  
Fuel supplement   337        
Certain Items Impacting Operating Expenses:              
Acquisition and integration costs   1,378       1,199  
COVID-19 costs   153       217  
Executive Board of Directors transition award   3,500        
Legal fees - non-routine   51        
Certain Items Impacting Total Other Income (Expense):              
Interest component of certain items         517  
Other (income) expense, net   2,298        
Total $ 11,450     $ 1,712  
Net of tax $ 8,473     $ 1,267  
Diluted EPS $ 0.26     $ 0.04  

(2) Adjusted EBITDA is defined as net income attributable to Amedisys, Inc. before net interest expense, provision for income taxes and depreciation and amortization, excluding certain items as described in footnote 1.
(3) Adjusted other operating income is defined as other operating income excluding certain items as described in footnote 1.
(4) Adjusted net income attributable to Amedisys, Inc. is defined as net income attributable to Amedisys, Inc. calculated in accordance with GAAP excluding certain items as described in footnote 1.
(5) Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share is defined as diluted income per share calculated in accordance with GAAP excluding the earnings per share effect of certain items as described in footnote 1.
(6) Adjusted EBITDA, adjusted other operating income, adjusted net income attributable to Amedisys, Inc. and adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share should not be considered as an alternative to, or more meaningful than, income before income taxes or other measures calculated in accordance with GAAP. These calculations may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate these non-GAAP financial measures in the same manner.


Primary Logo

Source: Amedisys, Inc.

Contact Information

Amedisys Corporate Headquarters
3854 American Way
Baton Rouge, LA 70816
(225) 292-2031
Amedisys Executive Office
209 10th Avenue S.
Suite 512
Nashville, TN 37203
Request Information